---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-387197"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-09-10T11:05:24+00:00"
generated_at: "2026-09-10T11:10:47.287410+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# EyePoint posts updated investor presentation with LUGANO Phase 3 data; specifics not disclosed in excerpt

## Summary
- EyePoint posted an updated investor presentation on September 10, 2026, on its website.
- Presentation titled 'LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses'.
- No specific efficacy, safety, or financial figures are included in the provided excerpt.
- DURAVYU is being studied for wet age-related macular degeneration in the LUGANO Phase 3 trial.

## SEC filing metadata
- accession: 0001193125-26-387197
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-09-10T11:05:24+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/0001193125-26-387197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-20260910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-387197
- JSON: https://secwatch.observer/filing/0001193125-26-387197.json
- Plain text: https://secwatch.observer/filing/0001193125-26-387197.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.